Literature DB >> 22882895

Chapter 7: Description of MISCAN-lung, the Erasmus MC Lung Cancer microsimulation model for evaluating cancer control interventions.

F W Schultz1, R Boer, H J de Koning.   

Abstract

The MISCAN-lung model was designed to simulate population trends in lung cancer (LC) for comprehensive surveillance of the disease, to relate past exposure to risk factors to (observed) LC incidence and mortality, and to estimate the impact of cancer-control interventions. MISCAN-lung employs the technique of stochastic microsimulation of life histories affected by risk factors. It includes the two-stage clonal expansion model for carcinogenesis and a detailed LC progression model; the latter is specifically intended for the evaluation of screenings. This article elucidates further the principles of MISCAN-lung and describes its application to a comparative study within the CISNET Lung Working Group on the impact of tobacco control on U.S. LC mortality. MISCAN-lung yields an estimate of the number of LC deaths avoided during 1975-2000. The potential number of avoidable LC deaths, had everybody quit smoking in 1965, is 2.2 million; 750,000 deaths (30%) were avoided in the United States due to actual tobacco control interventions. The model fits in the actual tobacco-control scenario, providing credibility to the estimates of other scenarios, although considering survey-reported smoking trends alone has limitations.
© 2012 Society for Risk Analysis.

Entities:  

Mesh:

Year:  2012        PMID: 22882895      PMCID: PMC3488877          DOI: 10.1111/j.1539-6924.2011.01752.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  21 in total

1.  How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment.

Authors:  Iris Vogelaar; Marjolein van Ballegooijen; Deborah Schrag; Rob Boer; Sidney J Winawer; J Dik F Habbema; Ann G Zauber
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

2.  Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model.

Authors:  Rafael Meza; William D Hazelton; Graham A Colditz; Suresh H Moolgavkar
Journal:  Cancer Causes Control       Date:  2007-12-06       Impact factor: 2.506

3.  The reliability of self-reported cigarette consumption in the United States.

Authors:  E J Hatziandreu; J P Pierce; M C Fiore; V Grise; T E Novotny; R M Davis
Journal:  Am J Public Health       Date:  1989-08       Impact factor: 9.308

4.  Multistage carcinogenesis and lung cancer mortality in three cohorts.

Authors:  William D Hazelton; Mark S Clements; Suresh H Moolgavkar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-05       Impact factor: 4.254

5.  Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II.

Authors:  W Dana Flanders; Cathy A Lally; Bao-Ping Zhu; S Jane Henley; Michael J Thun
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

6.  Cigarette smoking and changes in the histopathology of lung cancer.

Authors:  M J Thun; C A Lally; J T Flannery; E E Calle; W D Flanders; C W Heath
Journal:  J Natl Cancer Inst       Date:  1997-11-05       Impact factor: 13.506

7.  Estimates of global mortality attributable to smoking in 2000.

Authors:  Majid Ezzati; Alan D Lopez
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

8.  Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer.

Authors:  G J van Oortmarssen; J D Habbema
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

9.  The age distribution of cancer and a multi-stage theory of carcinogenesis.

Authors:  P ARMITAGE; R DOLL
Journal:  Br J Cancer       Date:  1954-03       Impact factor: 7.640

10.  Sex-differences in lung cancer cell-types? An epidemiologic study in Ireland.

Authors:  Zubair Kabir; Gregory N Connolly; Luke Clancy
Journal:  Ulster Med J       Date:  2008-01
View more
  8 in total

1.  Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models.

Authors:  William J McCarthy; Rafael Meza; Jihyoun Jeon; Suresh H Moolgavkar
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

2.  Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials.

Authors:  Kevin Ten Haaf; Joost van Rosmalen; Harry J de Koning
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-13       Impact factor: 4.254

3.  Chapter 8: The FHCRC lung cancer model.

Authors:  William D Hazelton; Jihyoun Jeon; Rafael Meza; Suresh H Moolgavkar
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

4.  Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control.

Authors:  Theodore R Holford; Lauren Clark
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

5.  Chapter 13: CISNET lung models: comparison of model assumptions and model structures.

Authors:  Pamela M McMahon; William D Hazelton; Marek Kimmel; Lauren D Clarke
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

6.  Predicting the Epidemiological Dynamics of Lung Cancer in Japan.

Authors:  Takayuki Yamaguchi; Hiroshi Nishiura
Journal:  J Clin Med       Date:  2019-03-08       Impact factor: 4.241

7.  The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

Authors:  Elisabeth van der Meijde; Alfons J M van den Eertwegh; Sabine C Linn; Gerrit A Meijer; Remond J A Fijneman; Veerle M H Coupé
Journal:  Cancer Inform       Date:  2016-06-15

8.  A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies.

Authors:  Kevin Ten Haaf; Mehrad Bastani; Pianpian Cao; Jihyoun Jeon; Iakovos Toumazis; Summer S Han; Sylvia K Plevritis; Erik F Blom; Chung Yin Kong; Martin C Tammemägi; Eric J Feuer; Rafael Meza; Harry J de Koning
Journal:  J Natl Cancer Inst       Date:  2020-05-01       Impact factor: 13.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.